GlobalData on MSN

MSD reports positive Phase III results for trial of Winrevair

MSD has announced positive Phase III HYPERION trial results showing Winrevair (sotatercept-csrk) reduced clinical worsening ...
GlobalData on MSN

MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate

Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.
pharmaphorum

Verona shareholders back $10bn MSD takeover

Investors in Verona – a specialist in respiratory medicines – overwhelmingly gave their blessing to MSD's $107-per-share ...

MSD wins SC Keytruda approval, but analysts sceptical on impact

Though Keytruda QLEX will be more patient-centric, analysts are sceptical of the drug’s capacity to stave off generic ...
pharmaphorum

FDA clears subcutaneous Keytruda in a boost to MSD

The FDA has cleared the new version for across most of the solid tumour indications already granted for Keytruda, which is ...
The Business Times

MSD drives smarter sustainability

A dedicated energy team is helping the global healthcare company to achieve net zero by 2045 Read more at The Business Times.
InvestorsHub on MSN

Evaxion Biotech Shares Jump Following MSD Vaccine Licensing Deal

Evaxion Biotech AS (NASDAQ:EVAX) surged 33% in premarket trading Thursday after announcing that MSD (NYSE:MRK) has exercised ...

MSD partners with Leadership Duncan 30 to restore Christmas parade route

Main Street Duncan has announced a partnership with Leadership Duncan Class 30 to change the city's Christmas parade route back to the traditional route. MSD said in a press release that due to “lack ...